Israeli Researchers Develop Experimental Blood Test for Early Breast Cancer
REHOVOT, ISRAEL — Researchers at the Weizmann Institute of Science and the Hebrew University of Jerusalem have developed an experimental blood test that could help identify early breast cancer and assess recurrence risk.
The research, announced November 11 and highlighted in November 19 coverage, involved Kaplan Medical Center and international collaborators.
The method examines epigenetic markers—chemical signals associated with how genes are regulated—on material released into the bloodstream when cells die.
According to the institute, researchers analyzed blood samples from 77 breast cancer patients and 30 healthy women, then expanded the patient sample collection.
The findings suggest potential for detecting cancer and identifying patterns associated with its return after treatment.
The test remains experimental. Larger prospective studies are needed to establish its effectiveness in routine screening. It is not an approved replacement for mammograms.
Reference:
weizmann-usa/news-media/news-releases/cancer-leaves-its-mark-new-blood-test-detects-early-breast-cancer-and-helps-predict-its-return/



